Loading…
Boston Scientific has closed its acquisition of Silk Road Medical for $27.50 per share, with an enterprise value of $1.18 billion, adding stroke prevention devices to its portfolio.
Boston Scientific agreed to acquire Silk Road Medical, a medical device company focused on stroke prevention via the TCAR procedure, for $27.50 per share, enterprise value of approximately $1.16 billion.
Genesis MedTech Group signed an exclusive distribution agreement with Silk Road Medical to introduce the ENROUTE Transcarotid Neuroprotection System and ENROUTE Transcarotid Stent System in China.